[Killing effect of Photofrin-Herceptin immunoconjugate on tumor cell lines in vitro].
OBJECTIVE
To study the specific killing effect of the Photofrin-Herceptin immunoconjugate on the tumor cells expressing HER-2.


METHODS
Photofrin (porfimer sodium) was covalently coupled to Herceptin (trastuzumab) via [1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide hydrochloride](EDCI) , and the killing effect of this conjugate was evaluated by means of MTT assay on SK-BR-3, MCF-7 and A549 cell lines expressing HER-2 at different levels.


RESULTS
The conjugate had weaker immunoactivity than Herceptin, but possessed stronger killing effect on the cell lines expressing HER-2 than Photofrin, Herceptin, as well as the mixture of Photofrin and Herceptin (P<0.05). In the cell lines negative for HER-2 expression, the killing effect of the conjugate was similar to that of Photofrin, Herceptin, and their mixture.


CONCLUSIONS
Photofrin-Herceptin immunoconjugate can specifically kill HER-positive cells in vitro.
Qian
Xin-yu
XY
Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Luo
Rong-cheng
RC
Li
Li-bo
LB
Liao
Wang-jun
WJ
Luo
Yu-ling
YL
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D017323:Dihematoporphyrin Ether / Q000494:pharmacology*; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017323:Dihematoporphyrin Ether; D018796:Immunoconjugates; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab